UNION therapeutics A/S: Financial statements 2013
CVR: 33963750
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
UNION therapeutics A/S (CVR 33963750) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 1,202,613 and a net result of DKK 359,099. Equity in the 2013 report amounted to DKK 410,153. The solvency ratio was 23%.
- Gross Profit
- DKK 1,202,613
- Profit/Loss
- DKK 359,099
- Equity
- DKK 410,153
- Total Assets
- DKK 1,786,847
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of November 29, 2013, RVT REVISIONSTJENESTEN A/S has stepped down as auditor of UNION therapeutics A/S.
UNION therapeutics A/S has published its interim report for the period October 10, 2011 to December 31, 2012.
On May 29, 2013, the company changed its name from SYNERCURE ApS to ANTIBIOTX ApS.
As of February 12, 2013, RSM PLUS P/S STATSAUTORISEREDE REVISORER has been appointed auditor of UNION therapeutics A/S.
About UNION therapeutics A/S
UNION therapeutics A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2011. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named AntibioTx A/S and ANTIBIOTX ApS. The management consists of Kim Domela Kjøller, Morten Otto Alexander Sommer and Rasmus Vendler Toft-Kehler. The board consists of Stig Løkke Pedersen (chair), Andrew John Oakley, Morten Otto Alexander Sommer and Peter Kristensen. The company's owners include MANJIN ApS, VENDLER ApS and T&W HOLDING A/S. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -11,802,644 and a net result of DKK -32,142,051 compared with DKK -98,922,000 the year before. Equity in the 2025 report amounted to DKK -147,650,138.